Abstract 568
Background
The risk of developing second primary malignancies (SPM) in patients (p) with breast cancer (BC) is higher than among the general population. Tamoxifen, chemotherapy and breast irradiation are associated with an increased risk of SPM. The aim of this study was to investigate the clinicopathological characteristics of the non BC SPM in p with primary diagnostic of BC.
Methods
We conducted a retrospective study in a cohort of 2,111 women with BC diagnosed between 1975 and 2014 in a regional cancer institute in Spain. We evaluated the incidence and pattern of SPM per Warren and Gates criteria, and the impact of breast cancer treatment on SPM.
Results
57p (2.7%) of the cohort developed a SPM, 13 of them (23%) had synchronous tumors and 44p (77%) had metachronous tumors. 10p (18%) developed a third primary malignancy and 1p (1.7%) developed a fourth primary malignancy. The most frequent SPM were hematological malignancies (HM) (11p, 19%), followed by endometrial (7p, 12.3%), gastric (7p, 12.3%), lung (6p, 10.5%), parotid tumors (6p, 10.5%) and melanoma (6p, 10.5%). The mean latency period for SPM was 62.7 months. HM were developed in 0.52% of the cohort of 2,111p. Myeloid neoplasms were diagnosed in 6p (0.28%). Among them, 1p developed chronic myeloid leukemia and 5p developed myelodysplastic syndromes (MDS), including refractory anemia with excess blasts-2 (2p) and 5q minus syndrome (2p). Lymphoid neoplasms were diagnosed in 5p (0.24%). The incidence of HM was similar in both anthracycline-treated and not treated p (0.48% and 0.58%, respectively). The incidence of HM in p treated with radiotherapy was higher than in p who did not receive radiotherapy (0.65% vs 0.19%).
Conclusions
HM are the most frequent non BC SPM in p treated from BC; frequently they are therapy related neoplasms. Deescalating chemotherapy and radiotherapy in BC and finding genetic markers of early malignancy detection are mandatory.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
740 - A real-world analysis of the treatment of advanced ovarian cancer with PARPIs
Presenter: Alejandra Martinez de Pinillos
Session: Poster Display session 2
Resources:
Abstract
5867 - Incidence of tumour BRCA1/2 variants in relapsed, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer
Presenter: Robert Morgan
Session: Poster Display session 2
Resources:
Abstract
2966 - Frequency of mutations in 21 hereditary breast and ovarian cancer susceptibility genes among 882 high-risk individuals
Presenter: Jihong Liu
Session: Poster Display session 2
Resources:
Abstract
1687 - BRCA testing of 1,284 Brazilian patients for hereditary breast and ovarian cancer in a routine diagnostic setting
Presenter: Fernanda Milanezi
Session: Poster Display session 2
Resources:
Abstract
3162 - A multi-center integrative study on cancer predisposition genes in Chinese patients with epithelial ovarian carcinoma
Presenter: Changbin Zhu
Session: Poster Display session 2
Resources:
Abstract
5993 - Incidental Early Occult Ovarian Cancer after Risk-Reducing Salpingo-Oophorectomy in BRCA1/2 Mutation Carriers followed in a Community Public Hospital
Presenter: Begona Grana Suarez
Session: Poster Display session 2
Resources:
Abstract
5334 - Response to chemotherapy in ovarian cancer (OC) patients with or without prior breast cancer (BC), stratified by BRCA mutation (BRCAm) status
Presenter: Angela George
Session: Poster Display session 2
Resources:
Abstract
4565 - Advanced ovarian cancer: is residual disease after debulking surgery affected by genetics factors involved in angiogenesis and immunity pathways?
Presenter: Michele Bartoletti
Session: Poster Display session 2
Resources:
Abstract
3251 - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study
Presenter: Fabrice Lecuru
Session: Poster Display session 2
Resources:
Abstract
3278 - Immune-Related Gene Expression Profiling after Neoadjuvant Chemotherapy (NACT) of Ovarian High-Grade Serous Carcinoma
Presenter: Luis Manso
Session: Poster Display session 2
Resources:
Abstract